Physician profile
Michelle P Jacoby
NPI 1841289857
$1,876.02
in general payments reported to CMS, 2019-2025
29 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $311 · 2021: $403 · 2022: $293 · 2023: $216 · 2024: $178 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.81 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $332.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.69 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $223.88 | 2021-2025 | |
| Lupin INC. | $140.16 | 2019-2021 | |
| Evofem Biosciences, INC. | $109.87 | 2021-2024 | Phexxi |
| Exeltis, USA INC. | $87.75 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $86.76 | 2019-2022 | |
| Astellas Pharma US INC | $58.10 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $56.19 | 2023-2024 | Myfembree |
| Scynexis, INC. | $54.52 | 2022 | |
| Hologic Sales and Service, LLC | $52.40 | 2020-2024 | Aptima |
| Amgen INC. | $46.00 | 2022-2025 | Evenity |
| Millicent US INC | $42.93 | 2020-2023 | Femring, Intrarosa |
| Sanara Medtech INC. | $29.85 | 2023 | Celleraterx |
| Organon LLC | $29.58 | 2023-2025 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.50 | 2022-2024 | |
| Mylan Pharmaceuticals INC. | $28.13 | 2021 | |
| Avion Pharmaceuticals | $26.48 | 2019 | |
| Allergan, INC. | $26.29 | 2019 | |
| Channel Medsystems, INC. | $25.47 | 2023-2024 | |
| Dysis Medical, INC. | $23.94 | 2021 | |
| Sage Therapeutics, LLC | $18.18 | 2024 | |
| Vertical Pharmaceuticals, LLC | $14.93 | 2019 | |
| Daiichi Sankyo INC. | $14.52 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.29 | 2023 | Exparel |
| Merck Sharp & Dohme LLC | $14.29 | 2020 | |
| Duchesnay USA Incorporated | $14.17 | 2019 | |
| Agile Therapeutics, INC. | $14.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.